StreetInsider.com News Articles

Emergent BioSolutions buys back $75M in senior unsecured notes

Thu, 03 Sep 2026 07:45:34 -0400

Emergent BioSolutions Inc. (NYSE: EBS) has completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028, according to a company statement.

The Gaithersburg, Md.-based company deployed approximately $68 million in cash for the repurchases, at an average price of 90.6% of face value. Following the transactions, the outstanding aggregate principal balance of the Senior Unsecured Notes has been reduced to approximately $364.7 million.

The repurchases were authorized by Emergent's Board of Directors. The company said it plans to monitor market conditions and evaluate the timing for refinancing the remaining outstanding notes, which mature in August

Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes

Thu, 03 Sep 2026 07:45:00 -0400

Repurchase reduces unsecured note balance to approximately $364.7 million
Management to discuss this key milestone and broader transformation progress at upcoming investor conferences

GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Senior Unsecured Notes”), following authorization granted by its Board of Directors. In total, Emergent deployed approximately $68 million of cash for the repurchases, resulting in an average repurchase price of 90.6% of

Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes

Thu, 03 Sep 2026 07:45:00 -0400

Repurchase reduces unsecured note balance to approximately $364.7 million
Management to discuss this key milestone and broader transformation progress at upcoming investor conferences

Form 8-K Emergent BioSolutions For: Aug 18

Tue, 01 Sep 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260901/27012962.html

Emergent BioSolutions gets $24M BARDA contract for anthrax vaccine

Tue, 01 Sep 2026 07:55:13 -0400

Emergent BioSolutions Inc. (NYSE: EBS) has received a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA) to supply its CYFENDUS® anthrax vaccine, according to a company press release.

BARDA is part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. The contract covers the supply of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness efforts.

CYFENDUS® received U.S. Food and Drug Administration approval in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis in individuals aged 18 through 65 when administered alongside recommended antibacterial drugs.

The

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

Tue, 01 Sep 2026 07:55:00 -0400

GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS^® (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness efforts. Anthrax remains a significant global biological threat due to its potential use in a bioterrorism event and its implications for public health and national security.

“This newly executed CYFENDUS^® contract modification with the U.S.

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

Tue, 01 Sep 2026 07:55:00 -0400

“This newly executed CYFENDUS^® contract modification with the U.S.

Emergent BioSolutions wins Canada NARCAN supply deal through 2029

Mon, 31 Aug 2026 07:55:30 -0400

Emergent BioSolutions Inc. (NYSE: EBS) has been awarded a standing offer by the Government of Canada to supply NARCAN® Nasal Spray, following a competitive procurement process, according to a company press release.

The agreement runs from October 1, 2026, through September 30, 2029, with an option to extend for two additional years. It replaces an existing five-year standing offer set to expire in September 2026.

Under the arrangement, authorized federal departments, agencies, Crown corporations, provinces, territories, and other designated public sector organizations across Canada may purchase NARCAN® Nasal Spray through individual call-ups.

NARCAN® Nasal Spray is a 4 mg intranasal naloxone spray indicated

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray

Mon, 31 Aug 2026 07:55:00 -0400

Standing offer expands access to opioid overdose emergency treatment across participating federal, provincial and territorial organizations in Canada

WINNIPEG, Manitoba, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply NARCAN® Nasal Spray. The standing offer is effective from October 1, 2026, through September 30, 2029, with an option to extend for an additional two years.

Under the standing offer, authorized federal departments, agencies, Crown corporations, provinces, territories and other designated

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray

Mon, 31 Aug 2026 07:55:00 -0400

Standing offer expands access to opioid overdose emergency treatment across participating federal, provincial and territorial organizations in Canada

Under the standing offer, authorized federal departments, agencies, Crown corporations, provinces, territories and other designated

Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day

Mon, 31 Aug 2026 07:54:00 -0400

Ready to Rescue campaign returns to U.S. college campuses with Release Recovery Founder and CEO Zac Clark
Partnership with professional baseball player Davis Schneider seeks to raise awareness of opioid poisoning preparedness across Canada

GAITHERSBURG, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- In recognition of International Overdose Awareness Day (IOAD), Emergent BioSolutions (NYSE: EBS) is reaffirming its commitment to expanding awareness of opioid overdose risks and increasing preparedness to help save lives. According to the World Health Organization, opioids are associated with nearly 80 percent of drug-related deaths worldwide, highlighting the continued need for education, preparedness and

Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day

Mon, 31 Aug 2026 07:54:00 -0400

Ready to Rescue campaign returns to U.S. college campuses with Release Recovery Founder and CEO Zac Clark
Partnership with professional baseball player Davis Schneider seeks to raise awareness of opioid poisoning preparedness across Canada

JPMorgan Reinstates Emergent BioSolutions (EBS) at Underweight

Fri, 21 Aug 2026 03:28:25 -0400

JPMorgan analyst Jessica Fye reinstates coverage on Emergent BioSolutions (NYSE: EBS) with a Underweight rating.

For an analyst ratings summary and ratings history on Emergent BioSolutions click here. For more ratings news on Emergent BioSolutions click here.

Shares of Emergent BioSolutions closed at $4.82 yesterday.

Form SCHEDULE 13G Emergent BioSolutions Filed by: AMERICAN CENTURY INVESTMENT MANAGEMENT INC

Fri, 14 Aug 2026 14:37:00 -0400

si-local-file:///var/storage/secattach/20260814/26929075.html

Form SCHEDULE 13G Emergent BioSolutions Filed by: AMERICAN CENTURY INVESTMENT MANAGEMENT INC

Fri, 14 Aug 2026 14:37:00 -0400

si-local-file:///var/storage/secattach/20260814/26929075.html

Form 3 Emergent BioSolutions For: Aug 05 Filed by: Duatschek Stephanie

Wed, 12 Aug 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26910012.html

Form 3 Emergent BioSolutions For: Aug 05 Filed by: Duatschek Stephanie

Wed, 12 Aug 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26910012.html

Emergent BioSolutions (EBS) PT Lowered to $10 at H.C. Wainwright

Mon, 10 Aug 2026 06:52:57 -0400

(Updated - August 10, 2026 6:52 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on Emergent BioSolutions (NYSE: EBS) to $10.00 (from $12.00) while maintaining a Buy rating.

The analyst commented: "Late last week, Emergent BioSolutions reported its 2Q26 financial results. The company recorded $234.3M in top-line revenue for the period, well ahead of guidance and soundly beating our forecast for top-line revenue totaling only $175M. However, Emergent lowered its full-year 2026 revenue guidance to $645-675M vs. the prior guidance range of $720-760M. This is driven mainly by the outlook for the naloxone franchise, which is slated to undergo

Emergent BioSolutions (EBS) PT Lowered to $10 at H.C. Wainwright

Mon, 10 Aug 2026 06:52:57 -0400

(Updated - August 10, 2026 6:52 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on Emergent BioSolutions (NYSE: EBS) to $10.00 (from $12.00) while maintaining a Buy rating.

Form 10-Q Emergent BioSolutions For: Jun 30

Thu, 06 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260806/26877363.html

Form 10-Q Emergent BioSolutions For: Jun 30

Thu, 06 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260806/26877363.html

Emergent BioSolutions (EBS) Tops Q2 EPS by 49c

Thu, 06 Aug 2026 02:17:44 -0400

Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.60, $0.49 better than the analyst estimate of $0.11. Revenue for the quarter came in at $234.3 million versus the consensus estimate of $186 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

Emergent BioSolutions highlights biological threat risks amid AI advances

Wed, 05 Aug 2026 16:08:46 -0400

Emergent BioSolutions (NYSE: EBS) issued a statement Aug. 5, 2026, calling for cross-sector collaboration on biological threat preparedness, citing concerns about advances in artificial intelligence and synthetic biology.

The company referenced a letter signed in June 2026 by AI executives and cross-industry leaders urging Congress to require safety screening and recordkeeping for synthetic DNA and RNA orders. The letter stated that "AI systems are improving rapidly, and alongside incredible benefits to science and medicine, there is a real possibility that the knowledge barriers which have historically prevented bad actors from obtaining biological weapons will meaningfully erode."

Emergent also cited remarks by Sandra

Emergent BioSolutions Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:07:00 -0400

Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior year
Second Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash impairment charge
Second Quarter 2026 Adjusted Net Income of $30.9 million improved 134% versus prior year
Second Quarter 2026 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 1400 bps and 900 bps, respectively, versus prior year
Second Quarter 2026 Adjusted EBITDA of $96.5 million and Adjusted EBITDA Margin of 41%, an

Emergent BioSolutions Reports Second Quarter 2026 Financial Results

Wed, 05 Aug 2026 16:07:00 -0400

Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior year
Second Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash impairment charge
Second Quarter 2026 Adjusted Net Income of $30.9 million improved 134% versus prior year
Second Quarter 2026 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 1400 bps and 900 bps, respectively, versus prior year
Second Quarter 2026 Adjusted EBITDA of $96.5 million and Adjusted EBITDA Margin of 41%, an